Dr. Gasparetto on Next Steps With Selinexor and Daratumumab in Multiple Myeloma

Cristina Gasparetto, MD
Published: Monday, Jan 08, 2018



Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses the next steps with selinexor and daratumumab (Darzalex) in multiple myeloma.

In a phase lb study, the combination of selinexor and daratumumab was evaluated in patients with relapsed/refractory multiple myeloma who were previously exposed to proteasome inhibitors and immunomodulatory drugs.

This combination will move onto a phase II study with more patients, says Gasparetto, in order to effectively evaluate response, side effects, and efficacy.
SELECTED
LANGUAGE


Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses the next steps with selinexor and daratumumab (Darzalex) in multiple myeloma.

In a phase lb study, the combination of selinexor and daratumumab was evaluated in patients with relapsed/refractory multiple myeloma who were previously exposed to proteasome inhibitors and immunomodulatory drugs.

This combination will move onto a phase II study with more patients, says Gasparetto, in order to effectively evaluate response, side effects, and efficacy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x